Vinblastine sulphate (Velbe)

Vinblastine sulphate (Velbe) is an intravenous anti-cancer drug derived from the periwinkle plant. It is being studied for the treatment of Kaposi’s sarcoma and lymphoma, alone or in combination with other anti-cancer drugs.1 Studies have also assessed the impact of injecting vinblastine directly into Kaposi’s sarcoma lesions in the mouth and throat, with positive results.2 3

Side-effects include low white blood cell counts and occasional hair loss. A single case report has also suggested that combining vinblastine with protease inhibitors may increase the risk of blood disorders and digestive system problems.4

References

  1. Volberding PA et al. Vinblastine therapy for Kaposi’s sarcoma in the acquired immunodeficiency syndrome. Ann Intern Med 103: 335-338, 1985
  2. Ramirez-Amador V et al. Intralesional vinblastine vs. 3% sodium tetradecyl sulfate for the treatment of oral Kaposi’s sarcoma. A double blind, randomized clinical trial. Oral Oncol 38: 460-467, 2002
  3. Gras R et al. Injection intra-lésionnelle de vinblastine dans le traitement d’une maladie de Kaposi laryngée associée au SIDA. Ann Oyolaryngol Chir Cervicofac 116: 291-294, 1999
  4. Kotb R et al. Life-threatening interaction between antiretroviral therapy and vinblastine in HIV-associated multicentric Castleman’s disease. Eur J Haematol 76: 269-271, 2006

Up a level
Back to contents
Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.